C3.ai, Inc. AI is once again in the spotlight after its shares jumped 17.9% over the past month, outpacing the broader S&P ...

US markets were mixed overnight, with the S&P 500 nudging its own all-time high, up less than 0.1% and the Dow Jones rising 0 ...

London stocks ended higher on Friday, supported by a positive shift in investor sentiment following US consumer confidence ...

London stocks had pared gains by midday on Friday, with GSK under the cosh. The FTSE 100 was flat at 8,971.33, having ...

The FTSE 100 index was up just 4.95 points at 8,977.59. The FTSE 250 gained 109.90 points, 0.5%, at 21,876.33, and the AIM All-Share climbed 2.54 points, 0.3%, at 771.47.

Reckitt Benckiser shares have lifted 2% or 110p to 5092p after the consumer goods giant secured a private equity buyer for ...

BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while ...

The fallers board was led by WPP, which slumped by 16% to its lowest level since 2009 after the marketing and advertising ...

Value investors should also note GSK's Price/Sales ratio of 1.9X. A company's earnings performance is important for value investors as well. For fiscal 2025, five analysts revised their earnings ...

In a report released yesterday, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report). The company’s shares closed yesterday at p1,434.00.

Comparatively, GSK underperformed the UK market's 3% decline and the UK Pharmaceuticals industry's 4.8% dip over the last year, highlighting industry-wide pressures.

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory uncertainties, GSK and Pfizer have decided to lay to rest their patent ...